STL Volume 26 Number 3

Bimekizumab is a novel treatment for moderate-to-severe plaque psoriasis that has shown promising efficacy and safety in clinical trials. By simultaneously targeting two components of the IL-17 pathway, IL-17A and IL-17F, the biologic can downregulate proinflammatory signaling and rapidly improve patients’ skin.

Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.

The update covers: Axatilimab IV injection - SNDX-6352 (Syndax Pharmaceuticals), Binimetinib tablets + encorafenib capsules - Mektovi® + Braftovi® (Pfizer Canada), Encapsulated cell therapy for Fabry disease - SIG-007 (Sigilon Therapeutics) and Oritavancin IV injection - Kimyrsa™ (Melinta Therapeutics).